Medicine & Life Sciences
5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine
18%
Antihypertensive Agents
9%
Antirheumatic Agents
24%
atezolizumab
100%
Biological Availability
10%
Breast Neoplasms
26%
Capsules
9%
Carcinoma
13%
Clarithromycin
12%
Clinical Trials
25%
Cytochrome P-450 CYP3A
11%
Delayed-Action Preparations
25%
Doxycycline
11%
Drug Interactions
10%
Drug Liberation
11%
Eudragit E PO
21%
Food
14%
Gastric Bypass
11%
Gastrointestinal Transit
30%
Healthy Volunteers
30%
human ERBB2 protein
12%
hydroxyitraconazole
23%
Immunotherapy
26%
Interleukin-1 Receptor-Associated Kinases
15%
Itraconazole
49%
Lipids
9%
Lung
10%
Lung Neoplasms
16%
Machine Learning
23%
Meta-Analysis
19%
methylmethacrylate-methacrylic acid copolymer
14%
Neutropenia
10%
Non-Small Cell Lung Carcinoma
33%
Obesity
14%
Omeprazole
12%
Oxycodone
27%
Patient Reported Outcome Measures
33%
Pharmaceutical Preparations
27%
Pharmacokinetics
89%
Population
22%
Progression-Free Survival
14%
Proton Pump Inhibitors
13%
Rheumatoid Arthritis
25%
Silicon Dioxide
11%
Simvastatin
12%
Sorafenib
12%
Survival
36%
Tablets
24%
Therapeutics
15%
tocilizumab
14%
Chemical Compounds
5-Fluorouracil
12%
Bioavailability
12%
Clarithromycin
15%
Dissolution
14%
Dose
7%
Drug
48%
Filament
5%
Food
12%
Itraconazole
15%
Liquid
11%
Oxycodone
34%
pH Value
13%
Pharmacokinetics
37%
Plasma Concentration
5%
Safety
8%
Simvastatin
15%
Sorafenib
15%
Time
15%
Time Schedule of Dosing
6%
Twice Daily
15%